Evidence map›Paper›PMID 40365701›Full record

ArticlePhotochemistry and photobiology

Predicting head and neck tumor nodule responses to TLD1433 photodynamic therapy using the image-guided surgery probe ABY-029.

Chanda Bhandari, Siddharth Soma, Maxwell Quaye, Alisher Talgatov, Gal Shafirstein, Kimberley Samkoe, Sherri McFarland, Girgis Obaid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chanda BhandariDepartment of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA.ORCID 0000-0002-4056-4754
Siddharth SomaDepartment of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA.
Maxwell QuayeDepartment of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA.
Alisher TalgatovDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas, USA.
Gal ShafirsteinDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Kimberley SamkoeThayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA.
Sherri McFarlandDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas, USA.
Girgis ObaidDepartment of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA.

Funding

Molecular Fluorescence-Guided Surgery PlatformR01CA167413 · NCI · DARTMOUTH COLLEGE · PI PAULSEN, KEITH D., SAMKOE, KIMBERLEY · 2013 to 2025
$5.7M
Molecular Imaging Guidance for Potentiating Chemoimmunotherapy in Pancreatic Cancer using Photodynamic PrimingR01EB034360 · NIBIB · UNIVERSITY OF TEXAS DALLAS · PI Girgis Obaid · 2024 to 2026
$1.6M
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsR00CA215301 · NCI · UNIVERSITY OF TEXAS DALLAS · PI OBAID, GIRGIS · 2020 to 2022
$721k
Cancer Prevention and Research Institute of Texas RP240498National Science Foundation 2102459National Science Foundation 2400127National Science Foundation 2503230NCI NIH HHS R00 CA215301NCI NIH HHS R01 CA167413NIBIB NIH HHS R01 EB034360NIH HHS R00CA215301NIH HHS R01CA167413NIH HHS R01EB034360
6 · The paper itself

Abstract

Incomplete surgical resection in head and neck cancer can lead to locoregional recurrence in >35% of patients. Approaches such as image-guided surgery (IGS) and post-operative photodynamic therapy (PDT) have been proposed to reduce recurrence rates. However, the PDT doses needed to eliminate all unresected diseases are not established. This in vitro proof-of-concept study aims to predict head and neck tumor nodule viability in vitro following PDT with TLD1433 using the IGS probe ABY-029. ABY-029 is an EGFR-specific affibody-IRDye800CW conjugate that has undergone Phase 0 evaluation studies in head and neck cancer, among others. TLD1433 is a ruthenium-based photosensitizer in a Phase II trial for non-muscle invasive bladder cancer. Here, we demonstrate that decreases in fluorescence emission of ABY-029 bound to MOC1 mouse head and neck cancer nodules in vitro can be predictive of TLD1433 PDT responses. Results show that photoactivation of TLD1433 produces reactive oxygen species (ROS) that reduce MOC1 nodule fractional viability in a manner that is inversely correlated with ABY-029 fluorescence intensity (Pearson's r = -0.9148, R

Indexed as

Head and Neck NeoplasmsPhotochemotherapyPhotosensitizing AgentsAnimalsCell Line, TumorErbB ReceptorsHumansMiceSurgery, Computer-AssistedErbB ReceptorsPhotosensitizing AgentsABY‐029head and neck cancerimage‐guided surgeryphotodynamic therapyTLD1433

Identifiers

PMID40365701
PMCPMC12353352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.